These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37020892)

  • 1. Evaluation of the anti-proliferative activity of 2-oxo-pyridine and 1'
    Raslan RR; Ammar YA; Fouad SA; Hessein SA; Shmiess NAM; Ragab A
    RSC Adv; 2023 Mar; 13(15):10440-10458. PubMed ID: 37020892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-
    Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A
    RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 6'-Amino-5'-cyano-2-oxo-1,2-dihydro-1'
    Dotsenko VV; Jassim NT; Temerdashev AZ; Abdul-Hussein ZR; Aksenov NA; Aksenova IV
    Molecules; 2023 Apr; 28(7):. PubMed ID: 37049923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
    Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
    Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and
    Al-Muntaser SM; Al-Karmalawy AA; El-Naggar AM; Ali AK; Abd El-Sattar NEA; Abbass EM
    RSC Adv; 2023 Apr; 13(18):12184-12203. PubMed ID: 37082377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
    Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
    Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
    Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
    PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
    Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with
    Alanazi MM; Elkady H; Alsaif NA; Obaidullah AJ; Alkahtani HM; Alanazi MM; Alharbi MA; Eissa IH; Dahab MA
    RSC Adv; 2021 Sep; 11(48):30315-30328. PubMed ID: 35493991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR
    Nasser AA; Eissa IH; Oun MR; El-Zahabi MA; Taghour MS; Belal A; Saleh AM; Mehany ABM; Luesch H; Mostafa AE; Afifi WM; Rocca JR; Mahdy HA
    Org Biomol Chem; 2020 Oct; 18(38):7608-7634. PubMed ID: 32959865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
    Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
    Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
    El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
    Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.